Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice

por Ching, L-M, Zwain, S, Baguley, B C
Publicado 2004

Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice.

por Ching, L. M., Joseph, W. R., Baguley, B. C.
Publicado 1992

Cytokinetic factors in drug resistance of Lewis lung carcinoma: comparison of cells freshly isolated from tumours with cells from exponential and plateau-phase cultures.

por Finlay, G. J., Wilson, W. R., Baguley, B. C.
Publicado 1987

The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice

por Zhao, L, Ching, L-M, Kestell, P, Baguley, B C
Publicado 2002

Necrosis in non-tumour tissues caused by flavone acetic acid and 5,6-dimethyl xanthenone acetic acid.

por Zwi, L. J., Baguley, B. C., Gavin, J. B., Wilson, W. R.
Publicado 1990

The use of vascularised spheroids to investigate the action of flavone acetic acid on tumour blood vessels.

por Zwi, L. J., Baguley, B. C., Gavin, J. B., Wilson, W. R.
Publicado 1990

Flavone acetic acid (FAA) with recombinant interleukin-2 (TIL-2) in advanced malignant melanoma. II: Induction of nitric oxide production.

por Thomsen, L. L., Baguley, B. C., Rustin, G. J., O'Reilly, S. M.
Publicado 1992

Nucleolar damage correlates with neurotoxicity induced by different platinum drugs

por McKeage, M J, Hsu, T, Screnci, D, Haddad, G, Baguley, B C
Publicado 2001

Paclitaxel induces nucleolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity

por Jamieson, S M F, Liu, J, Hsu, T, Baguley, B C, McKeage, M J
Publicado 2003

Selective toxicity of nitracrine to hypoxic mammalian cells.

por Wilson, W. R., Denny, W. A., Twigden, S. J., Baguley, B. C., Probert, J. C.
Publicado 1984

Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488).

por Philpott, M., Joseph, W. R., Crosier, K. E., Baguley, B. C., Ching, L. M.
Publicado 1997

Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid

por Ching, L-M, Cao, Z, Kieda, C, Zwain, S, Jameson, M B, Baguley, B C
Publicado 2002

Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum...

por Ching, L. M., Browne, W. L., Tchernegovski, R., Gregory, T., Baguley, B. C., Palmer, B. D.
Publicado 1998

Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs

por Screnci, D, McKeage, M J, Galettis, P, Hambley, T W, Palmer, B D, Baguley, B C
Publicado 2000

Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.

por Lash, C. J., Li, A. E., Rutland, M., Baguley, B. C., Zwi, L. J., Wilson, W. R.
Publicado 1998

Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid.

por Ching, L. M., Xu, Z. F., Gummer, B. H., Palmer, B. D., Joseph, W. R., Baguley, B. C.
Publicado 1995

Thalidomide increases both intra-tumoural tumour necrosis factor-α production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid

por Cao, Z, Joseph, W R, Browne, W L, Mountjoy, K G, Palmer, B D, Baguley, B C, Ching, L-M
Publicado 1999

Cell cycle times of short-term cultures of brain cancers as predictors of survival

por Furneaux, C E, Marshall, E S, Yeoh, K, Monteith, S J, Mews, P J, Sansur, C A, Oskouian, R J, Sharples, K J, Baguley, B C
Publicado 2008

Analysis of the TGFβ functional pathway in epithelial ovarian carcinoma

por Francis-Thickpenny, K M, Richardson, D M, Ee, C C van, Love, D R, Winship, I M, Baguley, B C, Chenevix-Trench, G, Shelling, A N
Publicado 2001

Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent

por Jameson, M B, Thompson, P I, Baguley, B C, Evans, B D, Harvey, V J, Porter, D J, McCrystal, M R, Small, M, Bellenger, K, Gumbrell, L, Halbert, G W, Kestell, P
Publicado 2003